30 March 2017
Reporter: Barney Dixon
CRISPR Therapeutics snags patent
The European Patent Office has confirmed it will grant CRISPR Therapeutics’s a patent “broadly” covering gene-editing technology.

The claims are directed to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings, including in cells from vertebrate animals such as human or mammalian cells.

It also covers composition claims for use in any setting, including claims for use in a method of therapeutic treatment of a patient.

Dr Rodger Novak, CEO of CRISPR Therapeutics, said: “We’re very pleased with the decision by the European Patent Office recognising the broad applicability of our foundational IP, and we look forward to pursuing additional cases to grant in other jurisdictions globally.”

The European patent application (13793997) was the subject of numerous third-party observations, including from the Broad Institute, in a bid to prevent its grant.

The underlying international patent application is based on the same US priority application that has been disputed in the US on behalf of CRISPR Therapeutics co-founder Dr Emmanuelle Charpentier and the University of California and University of Vienna.

The UK IP Office has signed off on the related applications.

It has granted a UK patent to the CRISPR/Cas9 single-guide gene editing system for uses in both non-cellular and cellular settings (2518764), and a second (2537000) to ‘chimeric’ CRISPR/Cas9 systems in which the Cas9 protein is modified to provide alternative DNA-modulating activities.

Dr Tyler Dylan-Hyde, chief legal officer at CRISPR Therapeutics, added: “We look forward to pursuing similar findings in the US under the first-to-invent system—and throughout the approximately 80 other countries our filings cover worldwide, including Europe, all of which are on a first-to-file priority system.”

The grant follows the US Patent Trial and Appeal Board’s (PTAB) ruling in February, which upheld two patents for CRISPR-Cas9 gene-editing technology because they were aimed at “distinctly patentable subject matter”.

More Europe news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
SUEPO takes the Netherlands to human rights court over EPO tension
09 May 2017 | Strasbourg | Reporter: Barney Dixon
SUEPO said that the Netherlands had upheld the EPO’s immunity “allowing a breach of fundamental rights on their soil”
UK IP Unjustified Threats Bill receives royal assent
04 May 2017 | London | Reporter: Barney Dixon
The bill will provide protection for legal advisors and IP owners who face damages for “unjustified threats”
Brunel University London scientists develop prior art checker
28 April 2017 | London | Reporter: Mark Dugdale
The tool, which currently has the working title of the Design Assistant for Semantic Comparison of Intellectual Property, could prevent costly patent litigation
Law firm sees rise in fintech patents
20 April 2017 | London | Reporter: Mark Dugdale
EMW's research revealed that the number of fintech patents filed worldwide is continuing to rise sharply, reaching 9,545 in 2016, up 6 percent from the 9,045 filed the year before
Patent trolls on the rise in EU, says coalition
06 April 2017 | Brussels | Reporter: Barney Dixon
There has been an ‘explosion’ of lawsuits from so-called trolls in Europe, according to IP2Innovate
Unwired Planet wins twice in one week
05 April 2017 | London | Reporter: Barney Dixon
The licensing company has secured two upper court rulings this week, one in the UK - with the country's first ever FRAND ruling - and another in the US
Apple ends Imagination deal
03 April 2017 | Hertfordshire | Reporter: Barney Dixon
Apple has ended a long-term licensing agreement with GPU manufacturer Imagination Technologies